Last reviewed · How we verify
APVO101
APVO101 is a dual checkpoint inhibitor that blocks both PD-1 and CTLA-4 pathways to enhance anti-tumor immune responses.
APVO101 is a dual checkpoint inhibitor that blocks both PD-1 and CTLA-4 pathways to enhance anti-tumor immune responses. Used for Advanced or metastatic solid tumors (Phase 3 development).
At a glance
| Generic name | APVO101 |
|---|---|
| Also known as | IB1001, Recombinant factor IX, IXINITY |
| Sponsor | Medexus Pharma, Inc. |
| Drug class | Dual checkpoint inhibitor |
| Target | PD-1 and CTLA-4 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
APVO101 simultaneously targets programmed death receptor-1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on T cells, removing inhibitory signals that tumors exploit to evade immune detection. By blocking both checkpoints, the drug aims to achieve greater T-cell activation and proliferation compared to single-agent checkpoint inhibition, potentially improving anti-tumor efficacy in solid tumors.
Approved indications
- Advanced or metastatic solid tumors (Phase 3 development)
Common side effects
- Immune-related adverse events (irAEs)
- Fatigue
- Diarrhea
- Rash
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- APVO101 CI brief — competitive landscape report
- APVO101 updates RSS · CI watch RSS
- Medexus Pharma, Inc. portfolio CI